A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies

By sjmartinez • August 2, 2024

Curigliano G, Jimenez MM, Shimizu T, Keam B, Meric-Bernstam F, Rutten A, Glaspy J, Schuler PJ, Parikh NS, Ising M, Hassounah N, Wu J, Leyk M, Chen X, Burks H, Chaudhury A, Otero J, Cabanas EG. A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies. ESMO Open. 2024 Jul 31;9(8):103643. doi: 10.1016/j.esmoop.2024.103643. Epub ahead of print. PMID: 39088985.

Tags: Hematology/Oncology, Keywords: LHC165; PDR001; TLR7 agonist; advanced, LHC165, PDR001, Publications, TLR7 agonist

Imaging Interoperability: #DitchtheDisk is a Health Equity Imperative for Lung Cancer Screening & Beyond

Tupper HI, Mendelson DS, Doo FX, Carlos RC, Bialecki B, Prosper AE, Moghanaki D, Servais EL, Flores EJ, Cummings AL. Imaging Interoperability: #DitchtheDisk is a[...]

Circulating tumor DNA detection of local recurrence in a patient with early stage triple-negative breast cancer

Alkassis S, Suresh Y, Lipsyc-Sharf M, Zhang S, Gianni C, Medford A, Bardia A, Ashouri S, Kapoor N. Circulating tumor DNA detection of local recurrence[...]

Prostate cancer incidence and outcomes among Vietnam veterans receiving care in the Veterans Health Administration

Green-Lott AY, Wadhwa A, Bailey AV, Kwan L, Haroldsen CL, Shelton JB, Lewis MS, Beenhouwer DO, Chamie K, Rose BS, Maxwell KN, Nickols NG, Yamoah[...]